Progenics Pharmaceuticals Inc. (PGNX)

7.62
0.13 1.74
NASDAQ : Health Technology
Prev Close 7.49
Open 7.44
Day Low/High 7.44 / 7.65
52 Wk Low/High 4.60 / 8.63
Volume 1.10M
Avg Volume 1.28M
Exchange NASDAQ
Shares Outstanding 73.72M
Market Cap 552.89M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

4 Names to Watch Ahead of Cancer Conference

4 Names to Watch Ahead of Cancer Conference

American Society of Clinical Oncology will see presentations from dozens of companies.

4 Names to Buy in a Refreshed Biotech Space

4 Names to Buy in a Refreshed Biotech Space

After a strong week for the biotech sector, these names have potential catalysts to move shares.

Relative Strength Alert For Progenics Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

Progenics Pharmaceuticals Announces Presentation Of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data At The 2018 Endocrine Society (ENDO) Annual Meeting

Progenics Pharmaceuticals Announces Presentation Of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data At The 2018 Endocrine Society (ENDO) Annual Meeting

Significant correlation between overall tumor biomarker response and achievement of the primary and secondary endpoints in pivotal study of AZEDRA

Commit To Purchase Progenics Pharmaceuticals At $6, Earn 17.4% Annualized Using Options

Commit To Purchase Progenics Pharmaceuticals At $6, Earn 17.4% Annualized Using Options

Investors eyeing a purchase of Progenics Pharmaceuticals, Inc. stock, but cautious about paying the going market price of $8.39/share, might benefit from considering selling puts among the alternative strategies at their disposal.

5 Stocks That Are Showing Signs of Reversing

5 Stocks That Are Showing Signs of Reversing

These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.

First Week of April 20th Options Trading For Progenics Pharmaceuticals (PGNX)

First Week of April 20th Options Trading For Progenics Pharmaceuticals (PGNX)

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the April 20th expiration.

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Reversal Offers Chance in 2 Small Biotechs

Reversal Offers Chance in 2 Small Biotechs

I've added to my positions in these names on yesterday's intraday silliness.

First Week Of PGNX August 2018 Options Trading

First Week Of PGNX August 2018 Options Trading

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the August 2018 expiration.

3 Tiny Explosive Biotech Stocks for 2018

3 Tiny Explosive Biotech Stocks for 2018

Sector M&A activity is likely to pick up next year benefiting the space.

Oversold Conditions For Progenics Pharmaceuticals (PGNX)

Oversold Conditions For Progenics Pharmaceuticals (PGNX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

4 Small-Caps on My Earnings Watch List

4 Small-Caps on My Earnings Watch List

We are coming my favorite part of earnings season -- when these small-caps report.

TheStreet Quant Rating: D (Sell)